Telmisartan and enalapril in type 2 diabetes

Abstract

Keywords

type 2 diabetes nephropathy telmisartan enalapril glomerular filtration rate.

Get full access to this article

View all access options for this article.

References

Barnett AH , Bain SC , Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.

Lacourciere Y. , Belanger A. , Godin C. et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy . Kidney Int 2000;58:762-9.

Pitt B. , Poole-Wilson PA , Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.

Dickstein K. , Kjekshus J. ; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.

Pfeffer MA McMurray JV , Velzquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003;349:1893-906 and erratum N Engl J Med 2004;350:203.

Parving HH , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

Lewis EJ , Hunsicker LG , Clark WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Brown NJ , Vaughan DE Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.

10.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy . N Engl J Med 1993; 329:1456-62 (and erratum N Engl J Med 1993;330:152).

11.

Ravid M. , Savin H. , Jutrin I. et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.

12.

Rippin J. , Bain SC , Barnett AH Rationale and design of Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. J Diabetes Complications 2002;16:195-200.

13.

Lacourciere Y. Telmisartan Cough Study Group. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999;53:99-103.